Quotient Clinical celebrates its 50th RapidFACT™ program
Quotient Clinical, the Translational Pharmaceutics™ Company, has commenced its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the development of this service.
RapidFACT was first developed in 2008, with the goal of transforming the processes by which drug product formulations are optimized. This service has now been proven to accelerate program timelines by at least 50 percent, and deliver significant associated cost savings. This has been achieved by the co-location of real-time GMP manufacturing and clinical testing, under Quotient’s Translational Pharmaceutics™ platform, which enables formulation selection to be underpinned by emerging clinical data.
RapidFACT has been successfully deployed in early development and life cycle management programs to develop oral, inhaled, dermal and ocular drug products. These programs have principally focussed on optimizing drug products for once- or twice-daily dosing, or on addressing problems related to poor solubility. RapidFACT studies have been commissioned by customers ranging from large pharmaceutical organizations to small biotechs in the USA, Europe and Japan.
Mark Egerton, CEO of Quotient Clinical, commented:
“RapidFACT was launched in response to the challenges our customers told us they were confronting in their development programs. We are pleased that the potential benefits we identified in 2008 have translated into real timeline reductions and cost savings in all of our RapidFACT programs. Ultimately, this approach is helping our customers to address many of the R&D productivity issues prevalent in the industry today.”